Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

NNC 90-1170 Mechanism of Action: A Double-blind, Randomized, Single-center, Placebo Controlled, Crossover Study to Examine Beta-cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes

This trial is conducted in the United States of America (USA). The aim of this trial is to assess the effect of NNC 90-1170 on beta-cell responsiveness to increasing blood glucose concentrations in subjects with type 2 diabetes.

Inclusion Criteria:

• Diagnosed with type 2 diabetes, either newly diagnosed with at least 2 months of diet or on OAD monotherapy for at least 3 months
• Body Mass Index (BMI): 24-35 kg/m^2 inclusive

Exclusion Criteria:

• SUBJECTS WITH TYPE 2 DIABETES
• Receipt of any investigational drug within three months prior to this trial
• Recurrent severe hypoglycemia as judged by the investigator
• Cardiac disease
• Use of any drug (except an OAD (oral anti-diabetic drug)) that in the investigator's opinion could interfere with the blood glucose level
• Haemoglobin maximum 10 g/L
• HbA1c above 12%
• Loss of more than 400 mL blood during the 3 months prior to trial start
• HEALTHY SUBJECTS
• Receipt of any investigational drug within 3 months prior to this trial
• Clinically relevant cardiac disease or any clinically significant abnormal ECG (electrocardiogram)
• Use of any drug that in the investigator's opinion could interfere with the blood glucose level
• Haemoglobin max. 10 g/L
• HbA1c at least 6%